IHH Healthcare Berhad provides healthcare services primarily in Asia, Central and Eastern Europe, the Middle East, and North Africa. It provides primary care services, including treatment of basic illnesses, routine check-ups, vaccination, and dental services. The company also offers secondary services, such as specialist consultation, local surgeries, emergency care, diagnostics and imaging services, and acute treatment; and tertiary care services comprising specialist consultative care, advanced treatment, complex surgery, and inpatient care services, as well as operates quaternary hospitals. In addition, it provides a range of ancillary services, including laboratory and pathology service...
Jalan Stesen Sentral 5
Kuala Lumpur Sentral
Kuala Lumpur, 50470
IHH Healthcare Berhad Announces Internal Reorganization of Group Structure
Dec 12 14
The Board of Directors of IHH Healthcare Berhad announced that Acibadem Labmed Saglik Hizmetleri ve Ticaret A.S., Blab Laboratuvar Hizmetleri A.S. and Histogenetics Acibadem Laboratuvar Hizmetleri A.S., indirect subsidiaries of IHH, had merged on 11 December 2014. Following the Internal Reorganisation, all assets and liabilities of Blab Laboratuvar and Histogenetics had been transferred to Acibadem Labmed and Blab Laboratuvar and Histogenetics were subsequently dissolved. Prior to the internal reorganization, Blab Laboratuvar and Histogenetics were wholly-owned direct subsidiaries of Acibadem Labmed. The internal reorganization was undertaken in order to streamline the Acibadem group structure and management. The internal reorganization will not have any effect on IHH’s issued and paid-up share capital and substantial shareholders’ shareholdings. There shall be no material effect on the group’s earnings and net assets for the financial year ending 31 December 2014. None of the directors and major shareholders of IHH and persons connected to them has any interest, direct or indirect, in the internal reorganization.
IHH Healthcare Berhad Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Announces Write Offs
Nov 25 14
IHH Healthcare Berhad reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's revenue was MYR 1,783,943,000 compared with MYR 1,671,718,000, a year ago. The increase in the revenue was attributed To year-on-year growth in patient volume and revenue intensity of existing operations and the commencement of operations of Acibadem Atakent Hospital and Pantai Hospital Manjung in January 2014 and May 2014 respectively. Profit before tax was MYR 205,806,000 compared with MYR 169,638,000, a year ago. Profit attributable to owners of the company was MYR 146,907,000 or 1.79 sen per diluted share compared with MYR 117,029,000 or 1.43 sen per diluted share a year ago. EBITDA was MYR 426,962,000 compared with MYR 393,918,000, a year ago.
For the nine months, the company's revenue was MYR 5,406,608,000 compared with MYR 4,976,318,000, a year ago. The increase in the revenue was attributed to year-on-year growth in patient volume and revenue intensity of existing operations and opening of Acibadem Atakent Hospital and Pantai Hospital Manjung in January 2014 and May 2014 respectively. Profit before tax was MYR 792,177,000 compared with MYR 591,367,000, a year ago. Profit attributable to owners of the company was MYR 515,063,000 or 6.29 sen per diluted share compared with MYR 401,059,000 or 4.92 sen per diluted share a year ago. EBITDA was MYR 1,351,483,000 compared with MYR 1,207,732,000, a year ago. Net cash generated from operating activities was MYR 1,158,869,000 compared with MYR 840,394,000, a year ago. Purchase of property, plant and equipment was MYR 590,549,000 compared with MYR 1,116,600,000, a year ago. Development and purchase of intangible assets was MYR 7,759,000 compared with MYR 10,700,000, a year ago. Purchase of investment properties was MYR 106,254,000 compared with MYR 214,229,000, a year ago. As on September 30, 2013, the company's net assets per share attributable to owners of the company was MYR 2.27 against MYR 2.22, as at December 31, 2013.
The company announced write off of property, plant and equipment of MYR 208,000, inventories of MYR 184,000 against write off of property, plant and equipment of MYR 30,000, inventories of MYR 299,000 for the same period of last year. Write off of trade and other receivables was MYR 1,545,000.